June 24, 2017 5:26 AM ET

Healthcare Equipment and Supplies

Company Overview of Calibra Medical, Inc.

Company Overview

Calibra Medical, Inc. develops and manufactures medical devices and technologies for the diabetes sector. It offers Finesse, an insulin delivery device. It was formerly known as Seattle Medical Technologies, Inc. and changed its name to Calibra Medical, Inc. in May 2005. The company was founded in 2004 and is based in Redwood City, California. As of July 13, 2012, Calibra Medical, Inc. operates as a subsidiary of LifeScan, Inc.

220 Saginaw Drive

Suite 1440

Redwood City, CA 94063

United States

Founded in 2004





Key Executives for Calibra Medical, Inc.

Calibra Medical, Inc. does not have any Key Executives recorded.

Calibra Medical, Inc. Key Developments

Johnson & Johnson Evaluates Options For Its Diabetes Care Companies

Johnson & Johnson (NYSE:JNJ) is considering potential alternatives for the diabetes care companies, specifically LifeScan, Inc., Animas Corporation, and Calibra Medical, Inc. It said the options may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together. It said all options will be evaluated to determine the best opportunity to drive future growth and maximize shareholder value.

Calibra Medical, Inc. Announces New Data Show On-Demand, Mealtime Insulin Delivery System Enabled More Than 50% of Patients to Report Improved Dose Compliance

Calibra Medical, Inc. announced that people with type 1 and type 2 diabetes who used the new OneTouch Via mealtime, on-demand insulin delivery system reported they missed fewer doses and felt less stress about dosing compared to multiple daily injections. Results of the Market Acceptance Evaluation (MAE) study also demonstrated that physicians were more likely to recommend the innovative insulin delivery device to patients who are not at A1C goals or who are new to rapid-acting insulin (RAI) therapy. The new OneTouch Via is a wearable, on-demand insulin delivery system in development that allows patients to discreetly deliver rapid-acting, or bolus, insulin at mealtimes by simply pressing two buttons on the device, accessible even through clothing. The thin, water-resistant patch can be worn continuously for up to three days, providing injection-free delivery of insulin when needed. The MAE study followed 44 patients with a median age of 57 years, who used the OneTouch Via patch for 60 days, instead of their bolus injection device (75% pen users and 25% syringe and vial users). Patients responded to insulin usage questionnaires at baseline, then after 1, 4 and 8 weeks. By weeks 4 to 8, more than half (58% and 52%, respectively) of study participants acknowledged dosing more often than they would with a pen or syringe with satisfaction rates increasing the longer they used OneTouch Via. Furthermore, 98% of patients said the patch let them dose discreetly in public, with 88% noting they worried less about forgetting insulin creating a less stressful disease management experience. The healthcare professionals who assisted with the study noted that they preferred the OneTouch Via over both insulin pens and syringes (75% and 100%, respectively) and would be likely to recommend it to their patients. The doctors also reported that they would start patients on mealtime insulin earlier because of the ease of use of the OneTouch Via patch. The U.S. Food and Drug Administration (FDA) approved the insulin delivery patch on April 10, 2012, for use by adults over 21 years of age with type 1 and type 2 diabetes. An additional Clinical Outcomes Study, being conducted across 60 trial sites in the U.S. and Europe, will measure the change in A1C levels, glycemic variability and patient reported quality of life seen in patients using OneTouch Via compared to insulin pens over the course of 24 and 44 weeks.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Calibra Medical, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.